Objective This systematic review aims to summarize current evidence on which naturally present cannabinoids contribute to cannabis psychoactivity, considering their reported concentrations and pharmacodynamics in humans.
Introduction

C
annabis is the third most widely used drug worldwide (United Nations Office on Drugs and Crime, 2015) , being its lifetime prevalence of use about 80.5 million Europeans (European Monitoring Centre for Drugs and Drug Addiction, 2012). Many European countries reported an increase in cannabis use during the last two decades (WHO, 2016) . Considered the most widely abused illicit drug, Cannabis sativa (Cannabis Sativa L.) is one of the oldest plants harvested by man (Appendino, Chianese, and Taglialatela-Scafati, 2011) and has been always accompanied by controversy due to its psychotropic effects-defined by the WHO as the "ability to change an individual's consciousness, mood or thinking processes" (WHO, 2004) .
Cannabis use has been associated with psychiatric, physical, and social impairment (Hall and Degenhardt, 2009; Hall, 2009; Volkow, Baler, Compton, and Weiss, 2014) . Otherwise, several potential therapeutic effects of cannabis have been found (Mechoulam and Hanuš, 2000) . While knowledge on and its therapeutic potentials has grown considerably in the last decades, its use is still polemic due to its potential harmful effects and its marked recreational use (Adams and Martin, 1996) . Moreover, difficulties in separating psychotropic effects from the therapeutic effects have been reported (Borgelt, Franson, Nussbaum, and Wang, 2013; Greenwald and Stitzer, 2000) .
One reason is cannabis' complex composition, containing more than 500 compounds from almost all the chemical classes, as for example mono-and sesquiterpenes, sugars, hydrocarbons, steroids, flavonoids, nitrogenous compounds and amino acids, simply fatty acids, among others (Appendino et al., 2011; ElSohly and Slade, 2005) . Exclusive of cannabis are the phytocannabinoids, being Δ-9-Tetrahydrocannabinol (9-THC) the most studied cannabinoid due to its known psycho activity (Dewey, 1987; Gaoni and Mechoulam, 1964; Hollister, 1987) . The rest of cannabinoids, around 100, have commonly been neglected (Mechoulam, 2005) . This is especially worrisome as consumers mostly smoke or ingest whole plant material, which presents variable proportions of cannabinoids.
This knowledge gap has also complicated cannabis health assessment. As no reliable and homogeneous registration systems exist, cannabis assessment remains focused on the frequency of consumption. One example is the definition for risky cannabis users given by the EMCDDA, which bases only on the frequency of cannabis use in the last month (European Monitoring Centre for Drugs and Drug Addiction, 2012) . Meanwhile the consumed quantity of cannabis, and more concretely the quantity of cannabinoids, remains unexplored.
One option already defined for other drugs as alcohol are standard units (Gual et al., 1999; Stockwell, Blaze-Temple, and Walker, 1991) , which consider the main constituent with implication on health. However for cannabis, consensus on which cannabinoids, other than 9-THC, may have implications on the sought psychoactive effects on humans, is still needed. Information on the influence of other cannabinoids on cannabis effects, considering their concentrations and effects on cannabis pharmacodynamics is still required.
In order to analyze the contribution of other cannabinoids to cannabis final health effects, we conducted a systematic literature review, which is intended to conclude which naturally present cannabinoids have shown psychoactive effects, considering their concentrations and their pharmacodynamics in humans.
Methods and materials
The information for this systematic review was gathered with an advanced document protocol in accordance with the PRISMA guidelines (Liberati et al., 2009; Urrútia and Bonfill, 2010) . Electronic research was performed consulting the following four scientific data bases: Medline (1950 -March 2016 , Scopus-Elsevier (2004 -March 2016 , Web of Science (1900 ( -March 2016 and COCHRANE (1991 ( -March 2016 . A combination of the following truncated terms were used as keywords to conduct the search: "Cannab*", "marijuana", "hash", "chemical", "structure" "constituent", "psycho" and "effect".
Selection criteria
All studies published before October 2015 were taken into account following the next parameters: (1) Studies on psychoactivity in humans with cannabinoids which are naturally present in cannabis or their pure synthetic alternative, (2) Pharmacodynamical properties of cannabinoids contributing to cannabis final psychoactive effects, (3) Reports of cannabis potency. Exclusion criteria: (1) Studies focusing mainly on pharmacokinetic properties of cannabinoids (2) Reviews or monographs. No language or publication date restrictions were applied.
Data extraction
Data was extracted by two reviewers (CC and HL) and two senior researchers (AG and MB) were asked in case of doubts. From the selected articles, the following data was extracted: authorship, year of publication, identified psychoactive substances, doses, administration forms, psychoactive effects, plant material used for the study and volunteers previous experience with cannabis.
Results
A total of 1484 unique entries were found, beyond those 87 fulfilled our inclusion criteria. After full-text-revision, 54 were rejected due to meet exclusion criteria, mostly because of being previous reviews (N=41). Finally, as shown 142 in Figure 1 , 40 articles were included in the literature review. The results are divided in three parts: 1) Naturally present cannabinoids affecting cannabis psycho activity; 2) Pharmacodynamical effects; and 3) Reported potencies of naturally present psychoactive constituents.
1) Naturally present cannabinoids affecting cannabis psycho activity
-Direct effects Delta-9-trans-Tetrahydrocannabinol (9-THC) dose-dependent psychoactive effects were observed on subjects after using the intravenous, oral and inhaled routes of administration (Table 2) . Also other administration routes like vaporization (Zuurman et al., 2008) and drinking cannabis tea (Hazekamp, Bastola, Rashidi, Bender, and Verpoorte, 2007) have been reported. and Cannabinol (CBN) produce psychoactive effects in humans but with less intensity than 9-THC (Table 1) (De Souza, Karniol, and Ventura, 1974; Hollister and Gillespie, 1973; Karniol and Carlini, 1973; Pérez-Reyes, 1973) . Potency ratio for 8-THC was estimated to be between 1:2 and 2:3 (8-THC: 9-THC) (Hollister and Gillespie, 1973; Karniol and Carlini, 1973) . Psychoactive effects of 8-THC were observed after intravenous and oral administration. CBN has a potency ratio of 1:10 (CBN: 9-THC), but psychoactive effects were not present after oral administration (Hollister, 1973) .
One metabolite of 9-THC -11-OH-THC-has psychoactive effects by its own if injected pure intravenously, observing faster and stronger psychoactive effects than after the administration of 9-THC (Lemberger, Martz, Rodda, Forney, and Rowe, 1973 ).
-Indirect effects Cannabidiol (CBD) administration was not followed by psychoactive effects neither after oral nor intravenous administration. CBD presents a modulating effect on 9-THC psychoactive activity, which has shown to depend on several factors. One example is the ratio CBD:9-THC or the order of administration of the cannabinoids, which affects the intensity of the modulating effect (Dalton, Martz, Lemberger, Rodda, and Forney, 1976; Ilan, Gevins, Coleman, ElSohly, and de Wit, 2005; Zuardi, Shirakawa, Finkelfarb, and Karniol, 1982) .
Another cannabinoid influencing 9-THC psychoactive effects is Δ-9-tetrahydrocannabivarin (THCV), which potency was estimated to be 25% of 9-THC psychoactive potency (Hollister, 1974) . However, evidence on THCV effects on 9-THC is still limited and contested, and suggest that THCV may have a mixed effect on 9-THC. A recent study showed that pre-treatment with THCV resulted in potentiating some of the effects produced by 9-THC, while minimizing others (Englund et al., 2016) .
2) Pharmacodynamical effects
Pharmacodynamical effects of naturally present psychoactive cannabinoids have shown to include psychological and systemically effects (Table 2 ).
-Psychological measures Pure 9-THC and whole plant material produced dose-dependent effects and feelings of intoxication and stimulation were the most often described. Other effects frequently observed were anxiety, sedation, deviations of psychomotor performance, memory impairment, worse- 
Directly related psychoactive metabolites of cannabis
11-OH-9-THC Lehmberger (1973) Intravenous Greater psychological effects than 9-THC with earlier onset.
Note.9-THC: 9-Delta-Tetrahydrocannabinol; 8-THC: 8-Delta-Tetrahydrocannabinol; CBN: Cannabinol; THCV: ∆-9-Tetrahydrocannabivarin, 11-OH-9-THC: 11-Hydroxy-Delta-9-Tetrahydrocannabinol. Zuardi (1982) Cannabis use at least on 15 days prior to the study Oral 9-THC: 0.5 mg/kg CBD: 1 mg/kg Combination of 9-THC (0.5 mg/kg) and CBD (1 mg/kg) THC anxiogenic, CBD antagonized subjective psychotropic effects of THC, pulse rate was not affected.
Studies comparing administration of pure 9-THC and whole plant material
Wachtel (2002) Cannabis use at least once in the last two months and at least 10 times in their lifetime.
Oral and smoking 9-THC: 8.4 mg, 16.9 mg CBN: 0.30% CBD:0.05%
Oral group: Volunteer report higher drug effect after pure 9-THC than after taking marijuana.
Smoking group: Pure 9-THC induces less drug effects than smoking marijuana, especially at the lower dose.
Chait ( Smoking and oral ingestion resulted in similar subjective effects. Smoking marihuana was rated in overall greater drug effects, greater heart rate and lower food intake.
Hart ( Smoking and oral ingestion resulted in similar subjective effects. Slightly more pronounced subjective effects with slower decrease over time were observed after smoking marijuana. Negative subjective effects and abstinence were identified only in the smoking group and not in the oral administration group.
Note. 9-THC: 9-Delta-Tetrahydrocannabinol; 8-THC: 8-Delta-Tetrahydrocannabinol ; CBN: Cannabinol; CBD: Cannabidiol; CBC: Cannabichromene.
ned prose recall, mood changes and decreased perceptual accuracy (Curran, Brignell, Fletcher, Middleton, and Henry, 2002; D'Souza et al., 2008; Hunault et al., 2009; Martin-Santos et al., 2012; Ramesh, Haney, and Cooper, 2013; Schaefer, Gunn, and Dubowski, 1977) . Articles comparing the effects of cannabis in different administration routes (oral vs smoked) conclude that oral administration of pure 9-THC produces lower subjective ratings than smoking whole plant material (Chait and Zacny, 1992; Hart et al., 2002) and does not result in craving and abstinence symptoms (Hart et al., 2002) .
When comparing the effects of pure 9-THC and whole plant material within same administration routes, minor differences in subjective effects were observed (Wachtel, ElSohly, Ross, Ambre, and Wit, 2002) . Basing on visual analog scales (Folstein and Luria, 1973) , orally ingested marihuana produces less subjective effects than pure oral 9-THC. In contrast, when smoked, marihuana resulted in greater subjective effects than smoking pure 9-THC. These results are consistent with other study results which have shown that cannabinoids as CBN lose their psychoactive effects if taken orally (Pérez-Reyes, 1973) .
Studies analyzing the influence of specific cannabinoids on 9-THC effects mostly focused on CBD. Although devoid of psycho activity (Pérez-Reyes, 1973) , several studies included in our review suggest that CBD has an potential influence on cannabis final effects. CBD has shown to antagonize and to modulate 9-THC effects, as for example memory impairment and prose recall (Morgan, Schafer, Freeman, and Curran, 2010) . Also anxiety and psychotic-like symptoms induced by 9-THC seem to be affected if CBD is present (Morgan et al., 2012; Zuardi et al., 1982) . However, CBD role seems complex as its effects not to depend only on its own concentration but also on the concentration of 9-THC as well the administration order (Bhattacharyya et al., 2010; Ilan et al., 2005 ).
-Systemic effects Dose-dependent cardiovascular effects, characterized by marked increases in heart rate were found in most of the volunteers participating in the cannabis studies. Smoking pure 9-THC induced less tachycardia than smoking whole plant material (Wachtel et al., 2002) . Other systemic symptoms were feeling hungry (Schwope, Bosker, Ramaekers, Gorelick, and Huestis, 2012), increased body sway as well as pupil size (Zuurman et al., 2008) .
Effects on the respiratory system were not described in the selected articles. Because cannabis is commonly smoked along with tobacco, some studies analyzed the potential interaction between the two drugs. Although little, available information indicates that tobacco increases the proportion of released cannabinoids (Van der Kooy, Pomahacova, and Verpoorte, 2009).
3) Reported potencies of naturally present psychoactive constituents -9-THC
With only a few exceptions, 9-THC is the cannabinoid present in the highest proportion. The highest concentrations of 9-THC identified in the review were in English cannabis powder (40.63%) and Dutch hashish (39.85%). Lower concentrations of 9-THC were reported in herbal cannabis, with a maximum of 25.5% of 9-THC found in New Zealand. Studies analyzing changes in 9-THC concentrations over time, describe high increases in the proportion of the main psychoactive cannabinoid (Bruci et al., 2012; Burgdorf, Kilmer, and Pacula, 2011; ElSohly et al., 2000 ElSohly et al., , 2016 Mehmedic et al., 2010) (Table 3 ).
-Other cannabinoids contributing to cannabis psychoactivity Concentrations of psychoactive cannabinoids other than 9-THC, were not always registered (Table 3) . When present, concentrations were generally low in comparison to 9-THC. One example is CBN, which maximum registered was of 7.7% present in confiscated hashish oil in the USA (Mehmedic et al., 2010) .
In contrast, although not psychoactive, concentrations of CBD were frequently registered. Over time, percentages of CBD in cannabis show a negative tendency, which is especially visible in herbal cannabis (ElSohly et al., 2016; Mehmedic et al., 2010; Niesink, Rigter, Koeter, and Brunt, 2015; Potter, Clark, and Brown, 2008) . In resin cannabis variable potencies were found depending on the origin of the derivate (Niesink et al., 2015; Pijlman, Rigter, Hoek, Goldschmidt, and Niesink, 2005; Tsumura et al., 2012) .
Discussion
Our review summarizes the current evidence on which naturally present cannabinoids contribute to cannabis final psychoactive effects. We have identified three cannabinoids (9-THC, 8-THC and CBD) and one human metabolite of 9-THC (11-OH-THC) which have shown psycho active effects. Beyond naturally present psychoactive constituents, 9-THC has the strongest psychoactive effects and is present in the highest concentration. Its metabolite 11-OH-THC produces more intense effects with an earlier onset. Cannabis psychological and systemically effects are primarily induced by 9-THC, while the contribution of other psychoactive cannabinoids is estimated to be very low.
Burdens in cannabis pharmacodynamical reports
Included studies present huge differences in crucial aspects of methodology, hindering direct comparison and more exhaustive analysis, as for example a meta-analysis. One of these aspects is volunteer's previous experience, which varied largely (going from cannabis use more than 10 times in lifetime to heavy and chronic cannabis users). When studying cannabis pharmacodynamia, previous experience is determinant to estimate acute and long-term effects, due to the presence of depot levels and tolerance (Abood and Martin, 1992; De Souza et al., 1974; Sharma, Murthy, and Bharath, 2012) . Methodological differences also affect how outcomes have been measured, going from self-ratings of subjective marihuana-like effects in the older studies (Pérez-Reyes, 1973) to much more complex descriptions using validated scales in the most recent retrieved articles (Englund et al., 2016) .
Another important aspect to be considered is the administration route. With direct impact on cannabinoids pharmacokinetic, differences play a key role in cannabis effects. One example is CBN which produces psychoactive effects if injected intravenously but not after oral administration (Pérez-Reyes, 1973) . Another example are abstinence symptoms which appeared after smoking marihuana but not after oral ingestion of pure 9-THC (Hart et al., 2002) . As cannabis extract is commonly smoked, these studies have important implications for the evaluation of cannabis health effects.
Moreover, 9-THC doses in the selected articles differed widely. In consequence, as cannabis has dose-dependent effects (D 'Souza et al., 2008; Wachtel et al., 2002) , variable symptoms were described. We cannot reject that due to cannabis complex composition even whole plant material containing similar 9-THC levels may have been different in regard to other cannabinoids. Characteristics as the origin of the plant material, part analyzed or cannabis derivate product should always be considered. Meanwhile, in order to permit comparisons between studies, also data on other cannabinoids but 9-THC should be registered.
Evaluating the role of other cannabinoids but 9-THC
Our review highlights that, by now, 9-THC is considered the main cannabinoid responsible for cannabis psychoactive effects. Research has focused on 9-THC although canna- Marijuana samples had less than 1.5% 9-THC in 1980 and rose to 4.2% 9-THC in 1997. Hashish and hash oil showed no specific potency trends. Other cannabinoids CBD, CBN and CBC showed no significant change in their concentration over the years.
ElSohly ( bis is mostly consumed as whole plant material. In order to avoid conflicting pharmacological reports, several authors have indicated that other plant cannabinoids need to be considered when evaluating cannabis effects (Eichler et al., 2012; Mechoulam, 2005; Turner, 1974) . Our review shows that in most occasions other psychoactive cannabinoids are not even analyzed. A common profile of cannabis effects could be found, including subjective effects (feeling 'high', stimulated) and systemic effects (changes in heart rate). Studies testing if 9-THC is the only responsible for cannabis psychoactivity conclude that administration of pure 9-THC and whole plant material produce similar effects, which do not significantly differ (Ilan et al., 2005; Wachtel et al., 2002) . Clinical implications due to 9-THC interaction with CBD is still being contested, and included articles evidence that CBD's acute modulating effects depends on several factors, as for example the concentration ratio, the administration form or the order of administration (Englund et al., 2013; Haney et al., 2016; Ilan et al., 2005; Zuardi et al., 1982) . Described effects reflect laboratory conditions, which may differ from real life conditions. In fact, reported data on concentrations of CBD indicate that especially in herbal cannabis, CBD is only present in minor concentrations. Therefore and as stated in previous reviews on the interaction of CBD and 9-THC, evidence suggests that CBD clinical implications on cannabis health outcomes need further research, that includes larger sample sizes and analyses of long-term effects (Haney et al., 2016; Hollister and Gillespie, 1975; Leweke, Mueller, Lange, and Rohleder, 2016; Zhornitsky and Potvin, 2012) .
Cannabis potencies and implications for health
In our article selection, the highest concentration used to analyze pharmacodynamical effects was 69 mg of 9-THC (23%) (Hunault et al., 2008 (Hunault et al., , 2009 . Even though high concentrations used in research may be lower than some of the registered potencies, as samples containing between 30% and 40% of 9-THC were reported by several authors. However, due to the fact that some registries correspond to policy seizures, data on potency may not be representative of common street cannabis.
Some authors affirm that when growing for recreational use, getting stronger cannabis has become a common target (Knight et al., 2010; Mehmedic et al., 2010; Pijlman et al., 2005) . Concentration changes have focused on 9-THC, while other cannabinoids maintain or decrease (Mehmedic et al., 2010) . Concentrations of 9-THC were mostly higher than the concentrations of other cannabinoids, which did mostly not exceed 8%.
Information about which harmful effects of cannabis are expected to get worsened by higher doses, especially in cases of chronic heavy use, need further research. Nonetheless, our review shows that in research there is a tendency to simulate real conditions of cannabis consumption.
One example is analyzing cannabis extracts mixed with tobacco (Hunault et al., 2008 (Hunault et al., , 2009 Van der Kooy, Pomahacova, and Verpoorte, 2008; Van der Kooy et al., 2009) or volunteers' own preparations (Morgan et al., 2012; van der Pol et al., 2013) .
Another issue of growing concern is the use of highly potent synthetic cannabinoids, which can result in serious harmful effects on health. Our review did not consider these compounds due to the fact that their prevalence of use in our context is much lower than the use of whole plant (Observatorio Español de la Droga y las Toxicomanías, 2015; Plan Nacional sobre Drogas, 2016).
Limitations and strengths of the systematic review
Our review has several potential study limitations. On the one hand, differences in study characteristics hindered equivalent data extraction for its comparison in a meta-analysis. On the other hand, publication bias and limitation of the data bases may have implicated some loss of information. However, our review was designed in order to find and assess relevant or high quality studies addressing the question of the review.
Our review has several positive aspects. To our knowledge it is the first systematic literature review focusing on psychoactivity, considering pharmacodynamical properties and potencies of several cannabinoids. Our study also points out that several aspects of cannabis psychoactivity are still unclear, mostly because research has not focused on how cannabinoids may influence individually on cannabis final effects.
Conclusions
Current evidence indicates that of cannabis naturally present constituents, 9-THC is the most potent psychoactive cannabinoid. Moreover, in comparison to other cannabinoids, its concentration in plant material is greatly higher. Therefore, when evaluating cannabis effects, 9-THC should be considered the main contributor to cannabis psycho activity.
Cannabis is the most abused illicit drug worldwide and constitutes an important public health problem. Standardized methodology is needed to overcome current burdens in cannabis research. Working on a standard cannabis unit which quantifies cannabis main cannabinoid with implication on psychoactivity is needed. This unit is expected to facilitate homogenization of cannabis registers, which is essential to improve epidemiological research and public health interventions.
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